Potential Neuroprotection for Equine Pituitary Pars Intermedia Dysfunction
Authors: Hetak Ashley, Fortin Jessica
Journal: The FASEB Journal
Summary
# Editorial Summary: Neuroprotection in Equine Cushing's Disease Pituitary pars intermedia dysfunction (PPID) remains the most prevalent endocrinopathy in horses, yet its underlying pathology—the progressive loss of dopamine-producing nerve cells in the pituitary gland—shares striking similarities with human neurodegenerative diseases. Hetak and Fortin's research identifies alpha-synuclein, a neuronal protein found at significantly elevated levels in horses with PPID, as the culprit: this protein misfolds and aggregates into toxic oligomers and fibrils that directly damage the dopaminergic neurons responsible for controlling ACTH secretion. Using protein extracts from affected horses, biophysical assays, and electron microscopy, the researchers pinpointed amino acid region 62–86 of equine alpha-synuclein as particularly susceptible to this toxic transformation and demonstrated that resveratrol, a natural polyphenol, reduced fibril formation by approximately 70% in laboratory conditions. These findings suggest a novel pharmacological avenue for neuroprotection in PPID horses, potentially slowing or preventing neuronal loss rather than merely managing symptoms via dopamine agonists; future work optimising lead compounds could ultimately offer horses a disease-modifying treatment rather than the palliative care currently available, transforming management of this prevalent condition.
Read the full abstract on the publisher's site
Practical Takeaways
- •This research identifies a potential novel mechanism for PPID pathogenesis involving alpha-synuclein toxicity, which may lead to new therapeutic targets beyond current dopamine agonist treatments
- •Natural products like resveratrol show promise in laboratory models of PPID-related neurodegeneration, but further development and in vivo testing are needed before clinical application
- •Clinicians should remain aware of emerging PPID research as it may explain why current treatments fail in some horses and could guide future management strategies
Key Findings
- •Horses with PPID have elevated alpha-synuclein levels in dopaminergic nerve terminals of the pituitary pars intermedia compared to healthy horses
- •Equine alpha-synuclein fragment 62-86 (NAC region) shows high propensity for toxic misfolding and aggregation
- •Resveratrol decreased thioflavin T fluorescence of equine alpha-synuclein fragment 62-86 by approximately 70% and reduced fibril formation on electron microscopy